ImmunityBio (IBRX) Receivables - Net (2014 - 2026)

ImmunityBio (IBRX) has 8 years of Receivables - Net data on file, last reported at $43.3 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 154.1% year-over-year to $43.3 million in Q1 2026; TTM through Mar 2026 was $43.3 million, a 154.1% increase from a year earlier, with the FY2025 full-year figure at $42.6 million, up 1703.86% from the prior year.
• Receivables - Net for Q1 2026 stood at $43.3 million, up from $42.6 million in the prior quarter.
• Over the last five years, Receivables - Net for IBRX reached as high as $43.3 million in Q1 2026 and fell as low as $600000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $14.1 million across 5 years, with a median of $3.3 million in 2024.
• Across the five-year window, Receivables - Net surged 72.17% in 2024 and soared 2041.92% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then jumped by 81.54% to $2.4 million in 2024, then surged by 1703.86% to $42.6 million in 2025, then rose by 1.64% to $43.3 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $43.3 million in Q1 2026, $42.6 million in Q4 2025, and $32.0 million in Q3 2025.